Background: New drugs to tackle the next pathway or mutation fueling cancer are constantly proposed, but 97% of them are doomed to fail in clinical trials, largely because they are identified by cellular or in silico screens that cannot predict their in vivo effect. Methods: We screened an Adeno-Associated Vector secretome library (> 1000 clones) directly in vivo in a mouse model of cancer and validated the therapeutic effect of the first hit, EMID2, in both orthotopic and genetic models of lung and pancreatic cancer. Results: EMID2 overexpression inhibited both tumor growth and metastatic dissemination, consistent with prolonged survival of patients with high levels of EMID2 expression in the most aggressive human cancers. Mechanistically, EMID2 inhibited TGFβ maturation and activation of cancer-associated fibroblasts, resulting in more elastic ECM and reduced levels of YAP in the nuclei of cancer cells. Conclusion: This is the first in vivo screening, precisely designed to identify proteins able to interfere with cancer cell invasiveness. EMID2 was selected as the most potent protein, in line with the emerging relevance of the tumor extracellular matrix in controlling cancer cell invasiveness and dissemination, which kills most of cancer patients.

Cappelletto, A., Alfì, E., Volf, N., Vu, T.V.A., Bortolotti, F., Ciucci, G., et al. (2024). EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 43(1), 15 [10.1186/s13046-023-02942-4].

EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening

Morello, Gaia;Tripodo, Claudio;
2024-01-10

Abstract

Background: New drugs to tackle the next pathway or mutation fueling cancer are constantly proposed, but 97% of them are doomed to fail in clinical trials, largely because they are identified by cellular or in silico screens that cannot predict their in vivo effect. Methods: We screened an Adeno-Associated Vector secretome library (> 1000 clones) directly in vivo in a mouse model of cancer and validated the therapeutic effect of the first hit, EMID2, in both orthotopic and genetic models of lung and pancreatic cancer. Results: EMID2 overexpression inhibited both tumor growth and metastatic dissemination, consistent with prolonged survival of patients with high levels of EMID2 expression in the most aggressive human cancers. Mechanistically, EMID2 inhibited TGFβ maturation and activation of cancer-associated fibroblasts, resulting in more elastic ECM and reduced levels of YAP in the nuclei of cancer cells. Conclusion: This is the first in vivo screening, precisely designed to identify proteins able to interfere with cancer cell invasiveness. EMID2 was selected as the most potent protein, in line with the emerging relevance of the tumor extracellular matrix in controlling cancer cell invasiveness and dissemination, which kills most of cancer patients.
10-gen-2024
Settore MED/08 - Anatomia Patologica
Settore MED/05 - Patologia Clinica
Cappelletto, A., Alfì, E., Volf, N., Vu, T.V.A., Bortolotti, F., Ciucci, G., et al. (2024). EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 43(1), 15 [10.1186/s13046-023-02942-4].
File in questo prodotto:
File Dimensione Formato  
13046_2023_Article_2942.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 901.54 kB
Formato Adobe PDF
901.54 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/621875
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact